


Serial No. 09/400,802

line 6 the Specification provides that the dose of GLP-1 necessary to normalize a patient's blood glucose level will depend on several factors. On page 3, line 16, different biological activities of GLP-1 are discussed including stimulating insulin sensitivity by enhancing glucose-induced insulin release. The GLP-1 receptor is discussed on page 21, beginning on line 3.

Respectfully submitted,



Mark J. Stewart
Attorney for Applicants
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division/MJS
Lilly Corporate Center
Indianapolis, Indiana 46285

March 20, 2001